Basilea Pharmaceutica AG (OTCMKTS:BPMUF) Sees Large Decline in Short Interest

Basilea Pharmaceutica AG (OTCMKTS:BPMUF) was the target of a significant drop in short interest during the month of October. As of October 15th, there was short interest totaling 96 shares, a drop of 73.7% from the September 30th total of 365 shares. Based on an average daily volume of 2 shares, the days-to-cover ratio is presently 48.0 days. Currently, 0.0% of the shares of the stock are sold short.

Basilea Pharmaceutica Price Performance

Shares of OTCMKTS BPMUF opened at $76.25 on Wednesday. The business’s 50 day moving average is $76.75 and its two-hundred day moving average is $69.45. Basilea Pharmaceutica has a 1-year low of $59.29 and a 1-year high of $77.40.

Basilea Pharmaceutica Company Profile

Basilea Pharmaceutica AG is a Switzerland-based biopharmaceutical company focused on discovering, developing and commercializing medicines for serious bacterial and fungal infections, as well as selected oncology indications. The company is headquartered in Basel and was established in 2000 as a spin-off from Roche.

Basilea’s principal products include Cresemba (isavuconazole), an antifungal medicine used to treat invasive fungal infections, and Zevtera (ceftobiprole), a cephalosporin antibiotic developed for several serious bacterial infections.